Trial · NCT02772419
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The change from baseline in nasal polyp score at Week 12 | baseline and 12 weeks post-dose | |
| Secondary | The change from baseline in nasal polyp score | Pre-dose and 4,8,12,16,20,24 weeks post-dose | |
| Secondary | The change from baseline in Computed tomography (CT) score | baseline and 12 weeks post-dose | |
| Secondary | Number of subjects discontinued from the study due to aggravation of eosinophilic chronic rhinosinusitis | Up to 24 weeks after dosing | |
| Secondary | Time to discontinuation (days) from the study due to aggravation of eosinophilic chronic rhinosinusitis | Up to 24 weeks after dosing | |
| Secondary | The change from baseline in Blood eosinophil count | Pre-dose and 4,8,12,16,20,24 weeks post-dose | |
| Secondary | The change from baseline in Nasal Airway Resistance | Pre-dose and 4,8,12,24 weeks post-dose | Nasal airway resistance (Pa/cm\^3/s) |
| Secondary | The change from baseline in the averaged values of the Olfactory thresholds | Pre-dose and 4,8,12,24 weeks post-dose | Olfactory thresholds are assessed by T\&T Olfactometer Test Score (Five kinds of smell with eight (5 to -2) phases). |
| Secondary | The change from baseline in the improvement of olfactory dysfunction | Pre-dose and 4,8,12,24 weeks post-dose | Olfactory dysfunction (1 to 5) is calculated by the Olfactory thresholds. |
| Secondary | The change from baseline in Sino-Nasal Outcome Test-2 (SNOT-22) | Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose | Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living) |
| Secondary | The change from baseline in Symptom score by Visual Analog Scale (VAS) | Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose | Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living) |
| Secondary | Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature | Up to 24 weeks after dosing | |
| Other | Serum concentration of benralizumab | Pre-dose and 4, 8, 12, 16, 20, 24 days post-dose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02772419/registered